Colvin MT et al. Atomic Resolution Structure of Monomorphic Abeta42 Exenatide Acetate Amyloid Fibrils. of epitope-specific enzymes towards endogenous focuses on as a strategy for site-specific protein modification without target gene manipulation, and enable potential future applications of sortase-mediated labeling of A peptides. Intro The ability to covalently improve proteins enables experts to efficiently interrogate and perturb their biological functions. Most purely chemical methods for protein labeling improve many proteins inside a biological mixture and yield heterogeneous products that are hard to characterize1. While systems such APR-246 as unnatural amino acid incorporation2,3, inteins4, small molecule-reactive peptides5 and epitope-specific enzymes6 enable chemo- and site-selective changes in biological systems, they typically require genetic manipulation of the protein of interest to expose an amber quit codon or peptide tag, potentially altering its biological properties and limiting applicability to settings in which target gene manipulation is possible. The ability to manipulate endogenous proteins inside a site-specific manner would enable target labeling actually in complex biological mixtures, and would be especially useful when genetic manipulation is definitely impractical. To explore this probability, we wanted to develop a versatile epitope-specific enzyme to recognize and covalently improve a peptide sequence natively present in a pathogenic protein. Sortase transpeptidases are a superfamily of enzymes widely distributed throughout Gram-positive bacteria7. sortase A (SrtA) is responsible for attaching proteins that contain a C-terminal LPXTG sorting sequence to the cell wall8. The enzyme cleaves between the threonine and glycine of the sorting sequence, forming an acyl-enzyme intermediate that consequently acylates the primary amine of the pentaglycine of the peptidoglycan9. SrtA shows a strong preference for its LPXTG sorting sequence10, but studies have exposed that it will accept a variety of glycine-based (and some non-glycine) nucleophiles11. These properties make SrtA a good tool for site-specific protein modification. Indeed, SrtA has been successfully utilized for both C-terminal and N-terminal protein labeling, as well as protein circularization and the semi-synthesis of multi-domain proteins.12C17 Executive of sortases for improved activity on both their cognate and novel substrates has been an area of active study for almost a decade18,19. Our group previously used candida display and fluorescence-activated cell sorting (FACS) to improve the kinetics of SrtA on LPETG20, and to evolve sortase variants that accept solitary amino acid substitutions at the second or fourth position of the acknowledgement sequence21. In this study, we wanted to reprogram the specificity of SrtA to covalently improve the Alzheimers disease-associated amyloid -protein (A). The formation of APR-246 A plaques in the central nervous system is the hallmark of Alzheimers disease (AD)22. Despite the clinical importance of A, its physiological functions and its part in AD pathogenesis are not clearly recognized23C25. The ability to improve A site-specifically might help illuminate its biological part, impede A plaque formation, or facilitate our understanding of AD pathogenesis. Since A monomers are mainly extracellular26, unstructured27,28, and contain a five-amino-acid sequence (LMVGG at residues 34C38) that shares features with sortases native acknowledgement sequence, sortase-mediated conjugation is an attractive strategy to accomplish site-specific modification of A. Over 16 rounds of development we generated a sortase variant, SrtA, that mediates the covalent changes of A peptides. We used SrtA to biotinylate and detect endogenous A in medical cerebrospinal fluid samples (CSF) at concentrations of 2C19 ng/mL. We also shown that SrtA-mediated conjugation of a hydrophilic pentapeptide to A42 greatly slows the initiation of detectable aggregation. This work establishes the development of sortase enzymes to site-specifically improve naturally occurring proteins without requiring changes of endogenous genes. Results Initial development of SrtA to recognize A We wanted to develop SrtA variants that improve A using candida display20,29C31 and fluorescence-activated cell sorting (FACS) (Number 1). Briefly, candida display a library of sortase variants conjugated to triglycine peptides with N-termini that are free for sortase-catalyzed reactions. The library is definitely then incubated with an N-terminally biotinylated target substrate and non-biotinylated off-target substrates. Sortase variants that catalyze transpeptidation between triglycine and the prospective substrate APR-246 biotinylate the surfaces of the candida cells that encode them. Activity on off-target substrates by promiscuous sortase variants leads to reduced biotinylation of the cells that encode them. After removal of cell surface-displayed sortases with TEV protease (Supplementary Number 1), cells are stained with fluorophore-linked streptavidin and the biotinylated cells encoding active and selective sortase variants are isolated by FACS (Extended Data Number 1). Open in a separate window Number 1. Yeast display strategy for sortase development.A population of yeast displays a library of ~107 SrtA variants. 1) Triglycine.